IN THE CLAIMS:

In accordance with the Revised Rules under 37 C.F.R. 1.121, please amend the claims as shown below and indicated as "currently amended." Also shown below are claims that may be original, cancelled, withdrawn, previously presented, new, and not entered.

1. (original) A high-throughput screening method of antahgonistic material of integrin comprising the steps of:

(a) immobilizing integrin $\alpha_{IIb}\beta_3$ and/or $\alpha_V\beta_3$ on protein chip;

(b) reacting ligand protein labeled with fluorescence and peptide pool of peptide library on the protein chip on which the integrin is immobilized;

(c) washing the protein chip with buffer solution after the reacting; and

(d) measuring the degree of ligand binding after the washing.

2. (original) The high-throughput screening method of claim 1, wherein the ligand is any one selected from the group consisting of vitronectin, fibronectin, collagen, laminin, Von Willebrand Factor (vWF) and fibrinogen.

3. (currently amended) HDVHK peptid (SEQ ID NO: 1), HGDVHK peptide (SEQ ID NO: 2), HHLLHK peptide (SEQ ID NO: 3), HGLVHK peptide (SEQ ID NO: 4) or HGDLHK peptide (SEQ ID NO: 5) having antagonistic activity of integrin $\alpha_V\beta_3$ and obtained by the screening method of claim 1 ~~or claim 2~~.

4. (original) A pharmaceutical composition for treating cancer, comprising peptide of claim 3.